INBX at a glance
Inhibrx Biosciences, Inc. (INBX, SEC CIK 2007919) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as September 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Inhibrx Biosciences, Inc. (INBX) reported revenue of $1.3 million (up 550.0% from FY2024) and a net loss of $140.1 million. Diluted EPS was -$9.04.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Inhibrx Biosciences, Inc. (INBX) shares worth $586.8 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Lappe Mark on September 28, 2026 of 1,500 shares at $98.88 per share.
- In the last 90 days, INBX insiders reported 14 open-market purchases ($5.5M) and 5 open-market sales ($279K) on Form 4, a net purchase of $5.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.3M
- +550.0% vs prior year
- Insiders · 90 days
- 14 buys · 5 sells
- Net +$5.2M
- 13F holders
- 24 funds
- $586.8M · −2 vs prior quarter
- Latest 8-K
- Sep 28, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- FDA BLA review risk: Form 483 observations issued during ozekibart inspections, potentially delaying review or triggering a complete response letter
- Regulatory safety risk: Prior grade 5 hepatotoxicity caused a partial clinical hold in the ChonDRAgon trial
- Commercialization risk: No marketed products and limited experience building U.S. launch infrastructure for ozekibart
- Development risk: Ozekibart and INBRX-106 remain in active clinical trials with uncertain safety and efficacy outcomes
- Financial risk: Clinical delays could exhaust resources needed to continue development or fund new collaborations
AI summary of the INBX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation posted September 28, 2026, providing investors with current business and pipeline materials
- Presentation distributed through conferences and investor meetings under Regulation FD
Item 7.01: Regulation FD Disclosure
- INBRX-106 clinical updates in first-line head and neck squamous cell carcinoma, a material development-stage program
- Disclosure delivered through a September 8, 2026 press release under Regulation FD
Item 8.01: Other Events
- INBRX-106 plus pembrolizumab delivered 48.3% cORR versus 26.5% for pembrolizumab alone
- Combination arm showed 13.8% complete responses versus none for control
Item EX-99.1: Item EX-99.1
- Phase 2 HNSCC data: cORR 48.3% with INBRX-106 plus pembrolizumab versus 26.5% monotherapy
- Median PFS 9.6 months versus 4.9 months, with six-month PFS 72.4% versus 42.8%
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the disclosed financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss widened to $36.7M, or $2.34 per share, from $28.7M, reflecting continued clinical-stage cash burn
- Cash rose to $219.5M by August 6 after $100.0M Oxford funding, extending resources for trials and potential commercialization
AI summaries of INBX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for INBX
Don't miss the next INBX filing
- Alerts as it files. A push when INBX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut INBX, by share count.
- Ask anything. An AI agent that reads every INBX filing and answers with sources.
INBX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Lappe Mark | Buy | Sep 28, 2026 | 1,500 | $98.88 |
| Lappe Mark | Buy | Sep 28, 2026 | 3,000 | $101.70 |
| Lappe Mark | Buy | Sep 25, 2026 | 3,324 | $98.87 |
| Lappe Mark | Buy | Sep 25, 2026 | 2,176 | $99.60 |
| Kayyem Jon Faiz | Buy | Sep 23, 2026 | 5,000 | $100.00 |
| Kayyem Jon Faiz | Buy | Sep 16, 2026 | 5,000 | $100.00 |
| MANHARD KIMBERLY | Sell | Sep 15, 2026 | 500 | $105.05 |
| MANHARD KIMBERLY | Sell | Sep 14, 2026 | 500 | $110.26 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $1.8M | $200K | $1.3M |
| Operating Income | - | -$331.4M | -$135.0M |
| Net Income | - | $1.7B | -$140.1M |
| Op. Margin | - | -165724.0% | -10386.5% |
| Net Margin | - | 843786.0% | -10773.5% |
| Balance Sheet | |||
| Total Assets | $307.9M | $180.8M | $146.5M |
| Equity | $43.5M | $133.6M | $8.0M |
| ROE | - | 1263.3% | -1752.2% |
| Per Share | |||
| EPS | $-20.48 | $112.62 | $-9.04 |
| Cash Flow | |||
| Operating CF | - | -$194.4M | -$129.8M |
| CapEx | - | $2.6M | $31K |
Source: XBRL data in Inhibrx Biosciences, Inc. (INBX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate INBX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $586.8M |
| Q1 2026 | 26 | $373.0M |
| Q4 2025 | 23 | $448.1M |
| Q3 2025 | 22 | $147.5M |
| Q2 2025 | 17 | $55.4M |
| Q1 2025 | 15 | $43.7M |
| Q4 2024 | 11 | $47.4M |
| Q3 2024 | 11 | $38.8M |
- Bank of America Corp+808.5K (+2474%)
- Goldman Sachs Group+243.1K (+256%)
- State Street Corp+89.6K (+16%)
- Vanguard Portfolio Management LLC+50.1K (+69%)
- Morgan Stanley+45.0K (+4%)
- Viking Global Investors−313.8K (-22%)
- Millennium Management−180.7K (-55%)
- D.E. Shaw & Co−55.1K (-71%)
- FMR LLC (Fidelity)−51.7K (-98%)
- Franklin Resources−20.9K (-61%)
- Citadel Advisors LLC−33.2K
- Mangrove Partners−5.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 149 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
INBX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 28, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| SC 13G | Aug 3, 2026 | - | - | |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
INBX SEC filings: frequently asked questions
Are INBX insiders buying or selling?
In the last 90 days, Inhibrx Biosciences, Inc. (INBX) officers, directors and 10% owners reported 14 open-market purchases worth $5.5 million by 3 insiders and 5 open-market sales worth $279,010 by 1 insider on Form 4, a net purchase of $5.2 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold INBX stock?
As of June 30, 2026, the largest Inhibrx Biosciences, Inc. (INBX) holders among the 13F filers tracked by SignalX were Morgan Stanley ($123.9 million), Viking Global Investors ($106.5 million), Bank of America Corp ($79.7 million), BlackRock ($78.3 million), State Street Corp ($60.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was INBX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Inhibrx Biosciences, Inc. (INBX) reported revenue of $1.3 million (up 550.0% from FY2024) and a net loss of $140.1 million. Diluted EPS was -$9.04. The figures come from the XBRL data in the 10-K.
What did INBX report in its latest 8-K?
Inhibrx Biosciences, Inc. (INBX) filed an 8-K on September 28, 2026 reporting Item 7.01 (Regulation FD Disclosure). Updated corporate presentation posted September 28, 2026, providing investors with current business and pipeline materials.
What are the latest INBX SEC filings?
Inhibrx Biosciences, Inc. (INBX) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on September 28, 2026.
What is INBX's SEC CIK number?
Inhibrx Biosciences, Inc. (INBX)'s SEC Central Index Key (CIK) is 2007919. EDGAR lists every INBX filing under that number.
Ask anything about INBX
The research agent reads INBX's filings, financials, insider trades and 13F holders, then answers with sources.